James Daly
Director/Board Member at ACADIA PHARMACEUTICALS INC.
Net worth: 2 M $ as of 2024-05-30
Profile
James M.
Daly is currently serving as an Independent Director at ACADIA Pharmaceuticals, Inc., argenx SE, and Madrigal Pharmaceuticals, Inc. He previously held positions as an Independent Director at Halozyme Therapeutics, Inc., Chimerix, Inc., and Bellicum Pharmaceuticals, Inc. He also served as the SVP-Global Marketing & Commercial Development at Amgen, Inc. from 2002 to 2011 and as the Chief Commercial Officer & Executive VP at Incyte Corp.
from 2012 to 2015.
Additionally, he has held positions at Coherus BioSciences, Inc., Amgen Ventures LLC, and Francis Cauffman, Inc. Mr. Daly obtained his undergraduate degree in 1983 and an MBA in 1985 from the State University of New York at Buffalo.
Known holdings in public companies
Company | Date | Number of shares | Valuation | Valuation date |
---|---|---|---|---|
2023-08-13 | 20,503 ( 0.02% ) | 908 078 $ | 2024-05-30 | |
2024-05-28 | 24,654 ( 0.01% ) | 372 275 $ | 2024-05-30 | |
2024-04-21 | 1,198 ( 0.01% ) | 282 920 $ | 2024-05-30 | |
ARGEN-X SE
0.00% | 2024-02-19 | 450 ( 0.00% ) | 166 439 $ | 2024-05-30 |
James Daly active positions
Companies | Position | Start |
---|---|---|
ACADIA PHARMACEUTICALS INC. | Director/Board Member | 2016-01-10 |
ARGENX SE | Director/Board Member | 2018-05-07 |
MADRIGAL PHARMACEUTICALS, INC. | Director/Board Member | 2019-06-26 |
Former positions of James Daly
Companies | Position | End |
---|---|---|
BELLICUM PHARMACEUTICALS, INC. | Director/Board Member | 2024-02-22 |
HALOZYME THERAPEUTICS, INC. | Director/Board Member | 2023-12-30 |
CHIMERIX, INC. | Director/Board Member | 2020-02-20 |
INCYTE CORPORATION | Corporate Officer/Principal | 2015-06-25 |
AMGEN INC. | Corporate Officer/Principal | - |
Training of James Daly
State University of New York at Buffalo | Masters Business Admin |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 8 |
---|---|
AMGEN INC. | Health Technology |
INCYTE CORPORATION | Health Technology |
CHIMERIX, INC. | Health Technology |
ACADIA PHARMACEUTICALS INC. | Health Technology |
HALOZYME THERAPEUTICS, INC. | Health Technology |
ARGENX SE | Health Technology |
COHERUS BIOSCIENCES, INC. | Health Technology |
MADRIGAL PHARMACEUTICALS, INC. | Health Technology |
Private companies | 4 |
---|---|
Francis Cauffman, Inc.
Francis Cauffman, Inc. Engineering & ConstructionIndustrial Services Francis Cauffman, Inc. provides architecture, interior design, and planning services. The firm specializes in healthcare, science & technology and corporate. The company was founded by Hughes D. Cauffman, James Francis and George Wikinson in 1954 and is headquartered in New York, NY. | Industrial Services |
GlaxoSmithKline LLC
GlaxoSmithKline LLC Pharmaceuticals: MajorHealth Technology GlaxoSmithKline LLC engages in discovering, developing, and delivering medicines, vaccines, and other healthcare products. It offers prescription medicines that treat various diseases, including cancer, HIV/AIDS, depression, diabetes, high blood pressure, herpes, asthma, migraine, and heart diseases, as well as stomach and skin problems, infections, and flu. It also provides vaccines for children and adults; and over-the-counter products. The company was founded in 1929 and is headquartered in Philadelphia, PA. | Health Technology |
Amgen Ventures LLC
Amgen Ventures LLC Investment ManagersFinance Amgen Ventures LLC (Amgen Ventures) is a venture capital firm, a subsidiary of Amgen, Inc. founded in 2004. The firm is headquartered in Thousand Oaks, California. | Finance |
Bellicum Pharmaceuticals, Inc.
Bellicum Pharmaceuticals, Inc. BiotechnologyHealth Technology Bellicum Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It focuses on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders. The firm uses its proprietary chemical induction of dimerization that controls components of the immune system in real time. Its product candidates include BPX-601, BPX-603, and Rivo-cel (rivogenlecleucel, formerly known as BPX-501). The company was founded by Kevin M. Slawin and David M. Spencer on July 14, 2004 and is headquartered in Houston, TX. | Health Technology |
- Stock Market
- Insiders
- James Daly